Positions

Overview

  • Dr. Solomon's clinical interest centers on the care of CF and non-CF bronchiectasis patients and the pursuit of continued inpatient medicine care of these patients in the acute care setting.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2017 Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice SitesAmerican Journal of Human Genetics.  100:751-765. 2017

    Research Overview

  • Dr. Solomon's research goal is the pursuit of translational sciences and an academic medical career focusing on the use of in vivo and in vitro ion transport, inflammatory, and rheological research techniques to explore mechanisms of disease and opportunities for novel treatments in CF, non-CF bronchiectasis patients and the pursuit of continued inpatient medicine care of these patients in the acute care setting.
  • Principal Investigator On

  • Functional Categorization of Ciliary Motion in PCD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2023
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study) (PROMISE-OB-18)  awarded by Cystic Fibrosis Foundation 2018 - 2023
  • Rare Mutations in Cystic Fibrosis: Overcoming Barriers to Personalized Medicine  awarded by Emory University 2018 - 2023
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2022
  • Evaluation of Predictors of Maternal-Fetal Outcomes in Cystic Fibrosis  awarded by University of Texas Southwestern Medical Center at Dallas 2019 - 2022
  • Private Grant  awarded by ELECTROMED, INC. 2020 - 2021
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2021
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2021
  • Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis (aka CASE.4.CF)  awarded by UNIVERSITY OF WASHINGTON 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • UAB Cystic Fibrosis Center For Care Teaching And Research (Adult)  awarded by Cystic Fibrosis Foundation 2017 - 2021
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • Potential Difference Measures Core for Advancing CFTR Therapeutics  awarded by Cystic Fibrosis Foundation 2020 - 2021
  • UAB Cystic Fibrosis Therapeutic Development Network Center for CFTR Detection  awarded by Cystic Fibrosis Foundation 2016 - 2021
  • A CF 3N Model of the Future: Proposal for Piloting a Learning Health System  awarded by CINCINNATI CHILDREN'S HOSPITAL 2020
  • Cystic Fibrosis Lung Transplant Transition LLC2  awarded by Cystic Fibrosis Foundation 2019 - 2020
  • Private Grant  awarded by ASTRAZENECA AB 2018 - 2020
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2018 - 2020
  • Cystic Fibrosis Learning Network: A CF C3N Model of the Future: Proposal for Piloting a Learning Health System  awarded by CINCINNATI CHILDREN'S HOSPITAL 2017 - 2019
  • Implementation Of The Depression And Anxiety Guidelines Award For A Mental Health Coordinator  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Standardized Treatment of Pulmonary Exacerbations II  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2019
  • Award for a Physical Therapist  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Private Grant  awarded by ELECTROMED, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Private Grant  awarded by PARION SCIENCES, INC. 2016 - 2018
  • Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2013 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Rare Cell Collection Protocol for CF Patients with Rare CFTR Mutations (RACE)  awarded by CYSTIC FIBROSIS FOUNDATION THERAPEUTICS., INC 2016 - 2017
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2016 - 2017
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2015
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2014 - 2015
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013 - 2014
  • Investigator On

  • Translational Program in CFTR-Related Airway Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2023
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Core A  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2021 - 2022
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2021
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Novel Therapeutic Approaches for Treatment of CF Patients with W1282X Premature Termination Codon Mutations  awarded by EMILY'S ENTOURAGE 2019 - 2021
  • A Multi-site Trial of Specialist Palliative Care in CF  awarded by Emory University 2020 - 2021
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation 2017 - 2021
  • A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)  awarded by Cystic Fibrosis Foundation 2020 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC 2019 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2018 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2020
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2017 - 2020
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")  awarded by SEATTLE CHILDREN'S HOSPITAL 2014 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Award for a Physical Therapist  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Implementation of Direct-to-Patient Telemedicine Healthcare Initiatives  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2017 - 2019
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Research Development Program  awarded by Cystic Fibrosis Foundation 2015 - 2019
  • Training and Equipment for the MBW sub-study of the PROSPECT Study.  awarded by Cystic Fibrosis Foundation 2014 - 2019
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)  awarded by Cystic Fibrosis Foundation 2014 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by ASTRAZENECA AB 2017 - 2018
  • Private Grant  awarded by CELTAXSYS, INC. 2016 - 2018
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Core C: Clinical & Translational Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • An Open Label N of 1 Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Ivacaftor in Combination with ALTALUREN (PTCD124) In Subjects with Nonsense Mutation Cystic Fibrosis  awarded by University of Pennsylvania 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2015 - 2017
  • Private Grant  awarded by Bayer HealthCare 2014 - 2017
  • Private Grant  awarded by PROGENRA, INC. 2016 - 2017
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)  awarded by Cystic Fibrosis Foundation 2011 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2014 - 2017
  • Private Grant  awarded by Gilead Sciences 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2016 - 2017
  • Private Grant  awarded by Bayer AG 2014 - 2017
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation 2015 - 2016
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2014 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2014 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2016
  • Therapeutic Development Center - UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation 2013 - 2015
  • UAB Research Development Program Component II - Overall Program  awarded by Cystic Fibrosis Foundation 2015
  • Nasal Epithelial Cells as an Outcome Tool for Individualized CFTR Therapies  awarded by Cystic Fibrosis Foundation 2014 - 2015
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2010 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2007
  • UAB Hospital, Residency 2010
  • University of Colorado Health Sciences Center, Postdoctoral Fellowship 2013
  • Full Name

  • George Solomon